Epithalon, Epithalone, AEDG
Evidence Grade C — Moderate human evidence. 60 published studies, 21 human. 0 registered clinical trials.
Epitalon is the most studied peptide in the Khavinson bioregulator programme from Russia — a synthetic tetrapeptide investigated for effects on telomerase (the enzyme that maintains chromosome protective caps) and lifespan in animal models. It has no approval from any major regulatory agency, and no controlled human clinical trials have been conducted.
60 published studies: 21 human, 36 animal, 9 in-vitro, 6 reviews
Epitalon has no marketing authorisation from any major regulatory agency. No controlled human clinical trials have been conducted. Animal lifespan studies in mice reported by the Khavinson group form the core evidence base.
The telomerase activation claims are based on in vitro studies and mouse models from a single research programme. Independent replication of the key findings has not been published. The relationship between in vitro telomerase activation and any clinical outcome in humans is not established. Products available through unregulated channels lack pharmaceutical quality assurance.
Research from the Khavinson group proposes that Epitalon may activate telomerase through effects on hTERT gene expression. Studies in cell culture have reported telomere elongation and telomerase activation. These observations are from in vitro and animal experiments published primarily by the originating research group and have not been independently replicated.
Research from the Khavinson group reports that Epitalon activated telomerase in cell cultures and extended lifespan in mice. These findings span decades and show a consistent direction, but the vast majority originate from a single research group. Recent independent work (2025) has begun to provide external validation of the telomerase mechanism. A paradox exists: telomerase activation is generally associated with cancer risk (cancer cells use telomerase to become immortal), yet the animal studies report reduced tumour incidence — a finding that remains unexplained. No properly controlled human trials, no formal pharmacokinetic data, and no independent replication of the lifespan claims exist. Products from unregulated sources lack pharmaceutical quality assurance.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
GHK-Cu has no pharmaceutical authorisation from any regulatory agency. It is widely available as a cosmetic ingredient in over-the-counter skincare products, where it is marketed for skin conditioning. A small study comparing GHK-Cu cream to vitamin C and retinoic acid creams reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable GHK-Cu have been completed. The compound's cosmetic use (topical, in formulated skincare products) should be clearly distinguished from its unregulated availability as an injectable research compound. These represent fundamentally different risk profiles.
FOXO4-DRI has no marketing authorisation. No human clinical trials have been conducted. The evidence comes from a single high-profile publication (Cell, 2017) demonstrating effects in three mouse models. The senolytic field is an active area of pharmaceutical research, but FOXO4-DRI faces significant challenges for clinical translation, including its large size (46 amino acids), manufacturing complexity, and the absence of human pharmacokinetic or safety data. Products available through unregulated channels — which would need to reliably synthesise a 46-amino-acid all-D-amino-acid peptide — face exceptional quality assurance challenges.
Afamelanotide is marketed as Scenesse (Clinuvel Pharmaceuticals, approved October 2019 in the US; previously approved in the EU in 2014). It is delivered as a bioresorbable subcutaneous implant administered every two months. Treatment is only available through a restricted distribution programme. In clinical trials, EPP patients on afamelanotide could spend significantly more time in direct sunlight without pain. EPP is a debilitating condition where even brief light exposure can cause hours of burning pain, and prior to Scenesse there was no approved treatment. Afamelanotide is related to the research compound Melanotan I, but is the only version that has undergone full regulatory approval for a specific medical condition.
